• 1
    Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MK, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:16181623.
  • 2
    Finkelstein JS, Arnold AL 1999 Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotrophin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84:12141219.
  • 3
    Lindsay R, Nieves J, Formica C, Hennerman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised clinical trial of the effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. Lancet 350:550555.
  • 4
    Lindsay R, Hodsman A, Genant H, Bolognese M, Ettinger M 1998 A randomised clinical trial of the 1–84 hPTH for treatment of postmenopausal osteoporosis. Bone 23(Suppl):1109.
  • 5
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled clinical trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620628.
  • 6
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:16271633.
  • 7
    Roe EB, Sanchez SD, del Puerto GA, Pierini E, Bachetti P, Cann CE, Arnaud CD 1999 Treatment of postmenopausal osteoporosis with human parathyroid hormone 1–34 and estrogen. Program and Abstracts of the 81st Annual Meeting of the Endocrine Society, San Diego, CA, U.S.A., June 12–15, 1999, p. 59.
  • 8
    Reeve J 1996 PTH: A future role in the management of osteoporosis? J Bone Miner Res 11:440445.
  • 9
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690709.
  • 10
    Sato M, Zeng GQ, Turner CH 1997 Biosynthetic human PTH(1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 138:43304337.
  • 11
    Meng XW, Liang XG, Birchman R, Wu DD, Dempster DW, Lindsay R, Shen V 1996 Temporal expression of the anabolic action of PTH in cancellous bone of ovariectiomized rats. J Bone Miner Res 11:421429.
  • 12
    Hock JM, Gera I 1992 Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7:6572.
  • 13
    Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S 1997 Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 99:26912670.
  • 14
    Hirano T, Burr DB, Turner CH, Sato M, Cain M, Hock JM, 1999 Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY 333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14:536545.
  • 15
    Frolick CA, Cain RL, Sato M, Harvey AK, Chandrasekhar S, Black EC, Tashjian AH, Hock JM 1999 Comparison of recombinant human PTH(1-34) (LY 333334) with a C-terminally substituted analog of human PTH-related protein (1-34) (RS 66271): In vitro activity and in vivo pharmacologic effects in rats. J Bone Miner Res 14:163172.
  • 16
    Gamse R, Bauer W, Cardinaux F, Feyen JHM, Gasser JA, Gombert FO, Seuwen K 1997 SDZ-PTS 893: Pharmacological profile of a highly potent novel PTH analog. J Bone Miner Res 12(Suppl):S317.
  • 17
    Yang KH, Stewart AF 1996 The PTH-related protein gene and protein products. In: BilezikianJP, RaiszL, RodanG (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, U.S.A., pp. 347376.
  • 18
    Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF 1996 Defining the physiologic roles of parathyroid hormone-related protein in normal physiology. Physiol Rev 76:127173.
  • 19
    Everhart-Caye M, Inzucchi SE, Guinness-Henry J, Mitnick MA, Stewart AF 1996 Parathyroid hormone-related protein(1-36) is equipotent with parathyroid hormone(1-34) in humans. J Clin Endocrinol Metab 81:199208.
  • 20
    Henry JG, Mitnick MA, Dann PR, Stewart AF 1997 Parathyroid hormone-related protein(1-36) is biologically active when administered subcutaneously to humans. J Clin Endocrinol Metab 82:900906.
  • 21
    Fraher LJ, Klein K, Marier R, Freeman D, Hendy GN, Goltzman D, Hodsman AB 1995 Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. J Clin Endocrinol Metab 80:6064.
  • 22
    Stewart AF 1996 PTHrP(1-36) as a therapeutic anabolic agent for the treatment of osteoporosis. Bone 19:303306.
  • 23
    Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ 1989 Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1–34 and PTH 1–34 on bone in rats. Endocrinology 125:20222027.
  • 24
    Weir EC, Terwilliger G, Sartori L, Insogna KL 1992 Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo. Calcif Tissue Int 51:3034.
  • 25
    Plotkin H, Gundberg C, Mitnick M, Stewart AF, 1998 Dissociation of bone formation from resorption during two-week treatment with hPTHrP(1-36) in humans: Potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab 83:27862791.
  • 26
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, 1987 Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 2:595610.
  • 27
    Turner CH, Burr DB 1993 Basic biomechanical measures in bone: A tutorial. Bone 14:595608.
  • 28
    Sato M, Zeng GQ, Rowley E, Turner CH 1998 LY35381 HCl: An improved raloxifene analog with bone efficacy complimentary to PTH(1-34). Endocrinology 139:46424651.
  • 29
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 337:16411647.
  • 30
    The writing group for the PEPI trial 1996 The effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:13891396.
  • 31
    Liberman UA, Weiss SR, Broll J, Minne HW, Qian H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:14371443.
  • 32
    Lindsay R, Nieves J, Henneman E, Shen V, Cosman F 1993 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 77:15351539.